Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
41 hedge funds and large institutions have $45M invested in Sierra Oncology, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 8 closing their positions.
32% more capital invested
Capital invested by funds: $34.1M → $45M (+$11M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
3% more funds holding
Funds holding: 40 → 41 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.2M |
| 2 |
Millennium Management
New York
|
+$1.34M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
+$880K |
| 4 |
Renaissance Technologies
New York
|
+$311K |
| 5 |
SIM
Spark Investment Management
New York
|
+$277K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.66M |
| 2 |
DM
Deerfield Management
New York
|
-$1.02M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$669K |
| 4 |
AIC
AWM Investment Company
New York
|
-$585K |
| 5 |
NC
Nexthera Capital
New York
|
-$468K |
SRRA Hedge Fund Activity: Q3 2017 in Review
41 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2017, worth a combined $45M — up 32% from $34.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SRRA positions and 8 closed out — a net gain of 1 holder — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.2M. The largest seller was Sabby Management, cutting an estimated $1.66M.
- 41 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2017, up from 40 in Q2 2017.
- Funds reported $45M of Sierra Oncology, Inc. Common Stock stock for Q3 2017, up 32% quarter-over-quarter.
- 9 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2017 and 8 closed out, a net change of +1 holder.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q3 2017 was Point72 Asset Management, an estimated $2.2M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q3 2017 was Sabby Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q3 2017.